Commentary: Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine

Wangqian Zhang¹, Cun Zhang²*

¹,²State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi’an, China, 710032

Article Notes
Received: May 03, 2018
Accepted: May 29, 2018

*Correspondence:
Dr. Cun Zhang
State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi’an, China
Telephone: +86 (0) 29-84773490
Fax: +86 (0) 29 84774773
Email: zhangcun@fmmu.edu.cn

© 2018 Zhang C. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.

Introduction

Breast cancer is the most frequent tumor worldwide and 252,710 women have developed the disease in the United States in 2017. Breast cancer is a heterogeneous disease and is clinically classified based on presence of hormonal receptors for estrogen and progesterone, and the expression/amplification status of the HER2 (human epidermal growth factor receptor 2)-protein/oncogene. HER2 is a tumor associated antigen which is over-expressed in a subset of patients with breast cancer (20–30%). There is abundant evidence that HER2 is a predictive target of clinical benefit to passive immune therapy with HER2-directed monoclonal antibodies (i.e., trastuzumab, pertuzumab, and TDM-1) alone or in combination with chemotherapy for the treatment of HER2 positive breast cancer.

Since HER2 is selectively overexpressed in cancer cells, and known to be effectively suppressed by antibodies targeting extracellular and intracellular domains, HER2 is also a good candidate for cancer vaccines. However, in the process of practical study of tumor vaccine, it suffered many kinds of setbacks that the immune systems do not cause tumor regression.

In our recent study, “Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine”, an attempt has been made to demonstrate that PD-L1/HER2 gene vaccine combination therapy synergistically generates marked tumoricidal effects against established HER2-expressing cancers and it provides new idea and evidence for designing tumor vaccine which not only can induce strong tumor-specific immune response, but also can block tumor immune escape.

HER2 directed vaccines

Several HER2-directed vaccines are currently undergoing clinical development in hopes to trigger robust Th1 response against HER2-positive breast cancer. For example, E75 (aa369–377) vaccine is a nine-amino acid peptide which elicits E75 immune response in activating CD8⁺ and CD4⁺ Th1 responses against HER2. One limitation of E75 vaccines is restriction to HLA-A2 and -A3 subtypes. Similarly, the GP2 (aa654–662) vaccine from the trans-membrane domain of HER2 also binds to HLA class I with low affinity. Responses to GP2 are usually short-lived likely because of the lack of robust activation of other components of the immune system, such as CD4⁺ Th helper cells. Furthermore, the over-expression of HER2 by breast cancer cells causing reduced levels of MHC class I, and decreased number of molecules of
the antigen processing and presenting machinery (APM), thus resulting in a tumor escape from immune-surveillance. However, in the process of practical study of tumor vaccine, it suffered many kinds of setbacks that the vaccine immunity effect independent employment effect is not good.

**Tumor Immune Escape and Immune Checkpoints**

As we know, there are many kinds of mechanism for tumor immune escape. For example, the lack of MHC I molecules on the tumor cell surface led to the activation barrier of tumor-specific CTL. Similarly, the lack expression of co-stimulatory molecules B7 family, some cytokines (TGF β) secreted by tumor cells or soluble cytokine receptor analogs all inhibited an effective anti-tumor immune response. In recent years, more and more studies aimed at the effects of the negative immune checkpoints on tumor immune escape. The negative immune checkpoints included CTLA-4, PD-1, the B7 family molecule (PD-L1, PD-L2), and CD4+CD25+Tregs. Their physiological function is to regulate the strength and breadth of the immune response, thus avoiding the damage of normal tissue. Tumor cells are capable of high expressing or inducing the production of immune system "negative regulation point" to escape the attack of immune system. There is growing evidence that blocking one or more "negative regulation point" can produce a lasting and effective anti-tumor immune response. For example, the antibody against CTLA-4, ipilimumab, has been approved by the US Food and Drug Administration (FDA) to treat metastatic melanoma. The antibody against programmed death-1 (PD-1), nivolumab and pembrolizumab have been approved by FDA to treat non-small-cell lung cancer.

**PD-L1 directed vaccines**

PD-L1, the homolog of B7.1/2 (CD80/86), shows the ability of co-inhibitory molecules and regulates the immune system. The PD-L1 protein is a cell surface glycoprotein which is only expressed on macrophage lineage of cells in normal tissues. Under physiological conditions, the PD-1/PD-L1 signaling pathway inhibits transmission of signals from the activated T cell receptor; plays a key role in self-tolerance and prevents T cells from over-activation and tissue damage during infection. The expression of PD-L1 is elevated in many types of cancer and is often correlated with poor patient prognosis. Ligation of PD-L1 on cancer cells with PD-1 on tumor-specific T cells has been demonstrated to suppress T-cell activation and proliferation, and to induce T-cell apoptosis. Tumor cells exploit this regulatory interaction as a mechanism of immune evasion. More recently, the antibody against PD-L1 (MPDL3280A) has been approved by FDA for the treatment of PD-L1-positive NSCLC. Our previous study also showed that the TT-rhPD-L1IgV vaccine induced high-titer anti-PD-L1 antibody, which could inhibit the growth of PD-L1-positive SP20 metastatic tumor. We thought that PD-L1 vaccine could not only kill the PD-L1-positive tumor cells like other common tumor-associated antigen vaccines, more importantly, it could block tumor immune escape and increase the body’s anti-tumor immune response by blocking PD-1/PD-L1 pathway whether the tumors expressed PD-L1 or not.

**Combination Therapy of hPD-L1 vaccine and HER2 gene vaccine**

As previously mentioned, PD-L1 acts as a tumor associated antigen and an immune-suppressor playing an important role in the immune escape of tumor cells. Our studies suggest that in tumor-bearing mice, EMT6 may secrete IFN-γ and promote self-expression of PD-L1 to evade the immune system attacks. Then, the positive feedback loops of tumor cells immune escape were formed and promote their own growth. The antibody induced by PD-L1 vaccine could not directly kill tumor cells, but combined with the PD-L1 located on the surface of tumor cells, to form a molecular barrier, blocked the mediated immune suppression and improved the reactivity of immune cell. As a DNA vaccine, HER2 gene vaccine not only possesses the ability to induce both T cell and humoral immune responses. After the combination therapy of hPD-L1 vaccine and HER2 gene vaccine, the rhPD-L1 protein vaccine increased the HER2-specific humoral and cellular immunity responses against EMT6 tumors, and thus, promoted the HER2 gene vaccine to induce a better anti-tumor immune response. So, the study suggests that PD-L1 vaccine might also enhance the efficacy of other tumor-associated antigen vaccine, antibody and immunotherapy approaches. However, the two newly published papers have demonstrated that in some tumors, the sequence and timing of antibody treatment targeting both costimulatory and inhibitory receptors is critical to success of the combined therapy, and sequential treatment has the combined benefit of both optimizing the antitumor immune response as well as potentially minimizing possible toxicity from acute cytokine release. Therefore, the role of the PD-L1 vaccine in combination with other immunotherapies in cancer patients and the sequence and timing of the PD-L1 vaccine treatment remain to be further studied.

**Conflict of interest**

The authors declare that there are no conflicts of interest.

**Acknowledgements**

The authors thank the members of the Biotechnology Center of the Fourth Military Medical University for their excellent technical support. This work was supported by the National Natural Foundation of China, NSFC81472484, 81472649, 81672864.
References